A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapyReportar como inadecuado




A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Medicine

, 5:28

First Online: 21 September 2007Received: 31 August 2007Accepted: 21 September 2007DOI: 10.1186-1741-7015-5-28

Cite this article as: Kawano, H., Komaba, S., Kanamori, T. et al. BMC Med 2007 5: 28. doi:10.1186-1741-7015-5-28

Abstract

BackgroundInactivated HVJ hemagglutinating virus of Japan; Sendai virus particles HVJ envelope vector; HVJ-E can incorporate and deliver plasmid DNA, siRNA, antibody and peptide and anti-cancer drugs to cells both in vitro and in vivo. We attempted to eradicate tumors derived from mouse colon cancer cells, CT26, by combining bleomycin BLM-incorporated HVJ-E HVJ-E-BLM with cisplatin CDDP administration.

MethodsCT-26 tumor mass was intradermally established in Balb-c mice. HVJ-E-BLM was directly injected into the tumor mass with or without intraperitoneal administration of CDDP. The anti-tumor effect was evaluated by measuring tumor size and cytotoxic T cell activity against CT26. Re-challenge of tumor cells to treated mice was performed 10 days or 8 months after the initial tumor inoculation.

ResultsWe found that three intratumoral injections of HVJ-E-BLM along with a single intraperitoneal administration of CDDP eradicated CT26 tumors with more than 75% efficiency. When tumor cells were intradermally re-injected on day 10 after the initial tumor inoculation, tumors on both sides disappeared in most of the mice that received the combination therapy of HVJ-E-BLM and CDDP. Eight months after the initial tumor eradication, surviving mice were re-challenged with CT26 cells. The re-challenged tumors were rejected in all of the surviving mice treated with the combination therapy. Cytotoxic T lymphocytes specific for CT26 were generated in these surviving mice.

ConclusionCombination therapy consisting of HVJ-E and chemotherapy completely eradicated the tumor, and generated anti-tumor immunity. The combination therapy could therefore be a promising new strategy for cancer therapy.

Electronic supplementary materialThe online version of this article doi:10.1186-1741-7015-5-28 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Hirokazu Kawano - Shintarou Komaba - Toshihide Kanamori - Yasufumi Kaneda

Fuente: https://link.springer.com/







Documentos relacionados